bioAffinity

bioAffinity Technologies Closes $4 Million Registered Direct Financing and Concurrent Private Placement of Common Stock

bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules bioAffinity Technologies, Inc. a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of…

Read MorebioAffinity Technologies Closes $4 Million Registered Direct Financing and Concurrent Private Placement of Common Stock
DIC

DIC Begins Global Rollout of ECOVART™ Low-Solvent Gravure Ink to Boost Productivity

DIC Commences Global Rollout of ECOVART™, a Low Solvent–Content Gravure Ink that Helps Improve Productivity DIC Corporation announced that it will commence the global rollout of gravure ink ECOVART™, which requires the addition of significantly less solvent than conventional gravure…

Read MoreDIC Begins Global Rollout of ECOVART™ Low-Solvent Gravure Ink to Boost Productivity
Transcripta

Transcripta Bio and Synfini Identify Lead Candidate Targeting Key Driver of Huntington’s Disease Progression in Weeks

Transcripta Bio & Synfini Collaborate to Identify a Lead Candidate Against a Key Driver of Huntington’s Disease Progression in a Matter of Weeks Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular disease, and Synfini, Inc., an…

Read MoreTranscripta Bio and Synfini Identify Lead Candidate Targeting Key Driver of Huntington’s Disease Progression in Weeks
Italfarmaco

Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeting Therapeutics for Neuromuscular, Fibrotic, and Rare Diseases

Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeting Therapeutics for Neuromuscular, Fibrotic, and Rare Diseases Italfarmaco S.p.A., a global pharmaceutical company with established expertise in histone deacetylase biology and therapeutic development, and VeriSIM Life, an AI-enabled drug discovery and…

Read MoreItalfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeting Therapeutics for Neuromuscular, Fibrotic, and Rare Diseases
AstraZeneca

AstraZeneca Opens New Global R&D Center in Cambridge’s Kendall Square

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts AstraZeneca announced the opening of its newest global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on the Company’s existing…

Read MoreAstraZeneca Opens New Global R&D Center in Cambridge’s Kendall Square
Mitsui

Mitsui Chemicals Launches InnoCell™ P-Type High-Oxygen Culture Plates for Faster Organoid Drug Discovery

Mitsui Chemicals Launches InnoCell™ P-Type High Oxygen-Permeable Culture Plates to Accelerate Organoid-Based Drug Discovery Mitsui Chemicals, Inc. has launched InnoCell™ P-Type, a new adherent cell culture plate in its InnoCell™ series of cell culture ware, as of October 1, 2026.…

Read MoreMitsui Chemicals Launches InnoCell™ P-Type High-Oxygen Culture Plates for Faster Organoid Drug Discovery
NeuWire

NeuWire Medical Receives FDA IDE Approval for STROKE-REWIRE Pivotal Study in Chronic Ischemic Stroke

NeuWire Medical Announces FDA IDE Approval for STROKE-REWIRE Pivotal Study in Chronic Ischemic Stroke NeuWire Medical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for STROKE-REWIRE, a pivotal study evaluating the…

Read MoreNeuWire Medical Receives FDA IDE Approval for STROKE-REWIRE Pivotal Study in Chronic Ischemic Stroke
Italfarmaco

Italfarmaco and JCR Pharmaceuticals Sign Exclusive License Deal for Hunter Syndrome Therapy

Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. announced an exclusive…

Read MoreItalfarmaco and JCR Pharmaceuticals Sign Exclusive License Deal for Hunter Syndrome Therapy
Summit

Summit Therapeutics Partners with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab with Datroway

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway Summit Therapeutics Inc. announced a clinical trial collaboration agreement with Daiichi Sankyo and AstraZeneca to evaluate ivonescimab, a novel, potential…

Read MoreSummit Therapeutics Partners with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab with Datroway
Longevica

Longevica Builds Advisory Board to Advance Human Health and Longevity Pipeline

Beyond Cellular Models: Longevica Capitalizes on World’s Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan Pipeline Longevica Therapeutics, a biotechnology company bridging the translation gap between empirical geroscience and human therapeutics, announced the formation…

Read MoreLongevica Builds Advisory Board to Advance Human Health and Longevity Pipeline